Mortality studies using ACE inhibitors in patients after myocardial infarction It is important to distinguish postmyocardial infarction studies from studies of chronic left ventricular dysfunction (table 1) . CON-SENSUS I,3 V-HeFT II,' and SOLVD5 6 provide important information on long term treatment of patients with chronic impairment of ventricular function. In these studies ischaemic heart disease was the predominant underlying cause of left ventricular dysfunction but, on average, patients were entered many months to years after myocardial infarction.
Postmyocardial infarction studies At least seven studies address the impact of ACE inhibitors on the mortality of patients after myocardial infarction7 (table 1).7-"2 Examination of this table shows the difficulty for physicians faced with numerous trials, identified by a myriad of acronyms, to apply appropriately the findings from such studies to their everyday practice. In addition, frequent additional analyses may add to their uncertainty. '3 We would like to make clear what is known and can be securely put into practice, distinguishing fact from opinion and extrapolation when a more guarded approach is appropriate.
Will all patients benefit from treatment with ACE inhibitors after myocardial infarction? Four studies, CONSENSUS II, ISIS-4, GISSI-3, and the Chinese captopril study, have tested a strategy of essentially treating "all patients" after myocardial infarction with an ACE inhibitor. Even in these, however, some selection has been imposed, particularly in excluding patients with low blood pressure.
CONSENSUS II offers the most overtly unselected population of patients with presumed myocardial infarction. They were given placebo or intravenous enalaprilat within hours of their myocardial infarction immediately after completion of thrombolysis, followed by oral enalapril. On average, treatment began 15 would not have received treatment in ISIS-4 and GISSI-3. Finally, the findings of CONSENSUS II were presented and later published during the recruitment for ISIS-4 and GISSI-3, which may have influenced selection.
The preliminary findings of the ISIS-4 and GISSI-3 trials were reported at the American Heart Association's meeting in Atlanta (November 1993) (table 1). Initial data from both studies showed that mortality was reduced but the effect was small and even with data on nearly 60 000 patients in ISIS-4 and 20 000 in GISSI-3, significance values were only just within the conventional 5% levels. At the same meeting the preliminary Chinese captopril study findings (table 1) were reported and even after studying 10 000 patients no significant benefit of captopril was apparent. When all three trials are combined, however, a more statistically reassuring but numerically small benefit emerges. Treating 1000 patients prevented about five deaths.
Before individual clinicians blindly accept that they will give ACE inhibitors to all their patients for this small benefit, or alternatively reject the idea of a treatment with such small benefit against cost and inconvenience to the patient, the definitive findings of two other published major studies should be considered.
SAVE STUDY
In the SAVE study patients were carefully selected on the basis of a reduced radionuclide ejection fraction (<40%), and they had no clinical signs or symptoms of heart failure at the time of randomisation. Before randomisation all patients had a test dose of captopril and an exercise test for ischaemia. Some 25% of patients underwent angioplasty or coronary artery bypass surgery before randomisation into the trial. Treatment with captopril was started on average 11 days after myocardial infarction and follow up was for an average of 42 months. The risk reduction in total mortality was 19% (95% confidence interval 3% to 32%; P = 0 0 19), but no effect was apparent until almost one year into treatment. In the AIRE study there was a 27% (1 1% to 40%) risk reduction in mortality from all causes in patients receiving ramipril. The finding was highly significant on a log rank test (2P = 0002). An important observation was that the mortality curves separated early. Although not part of the primary analysis, a prespecified analysis of early mortality showed a 29% risk reduction in mortality (2P = 0 053) even by 30 days. A second analysis on mortality between 30 days and study close, biasing the findings very much against the drug, suggested a further ongoing benefit from ramipril beyond the effects of the first month of treatment. Ramipril prevented both sudden (presumed arrhythmic) death and death associated with progression to severe or resistant heart failure. Importantly, ramipril's effects were independent of thrombolysis or the use of aspirin, men and women gaining similar benefit. Treatment of 1000 patients for one year prevented some 40 deaths.
A case for selecting patients at high risk? Patients after a myocardial infarction do not form a homogeneous group. Most will make a good recovery and by six months to one year will have a prognosis similar to any comparable age group of patients with known ischaemic heart disease. 16 One substantial readily identifiable group of high risk patients are those who manifest some clinical evidence of heart failure after a myocardial infarction. A recent study undertaken since the introduction of thrombolysis showed that the mortality in patients with evidence of heart failuredenoted by breathlessness, a third heart sound, crackles at the bases, and a need for a diuretic-was extremely high at 46% in the first year. In many of these patients thrombolysis had probably been unsuccessful, large infarcts ensued, and death occurred within the first 48-72 hours. At the other extreme some would have had only transient failure with minimal damage to their ventricles. The prognosis overall of patients who manifest some clinical evidence of heart failure, even if transient, but survive the first few days after a myocardial infarction is 20-25% in the first year. The AIRE study showed that physicians using everyday clinical criteria could identify these patients and that treatment with the ACE inhibitor ramipril brought substantial benefit.
Another major predictor of outcome after myocardial infarction is left ventricular ejection fraction.'7 Whereas clinical criteria may be more powerful than ejection fraction in predicting outcome (table 2) , the two together select a group at even higher risk.'8 For any given ejection fraction the observation of heart failure on clinical examination or chest radiology more than doubles subsequent mortality at one year. '9 20 It is important to recognise, however, that reduced ejection fraction and clinical symptoms identify different but overlapping populations.2' Neither ejection fraction nor symptoms were used in the random allocation of patients to the arms of the GISSI-3 or ISIS-4 studies, but some information was recorded on these aspects. Subgroup analysis is, however, fraught with difficulties. Thus, for example, in GISSI-3 only women had a significant reduction in mortality with lisinopril, yet no benefit accrued to women in SAVE. In GISSI-3 some three quarters of patients during their stay in a coronary care unit never showed clinical evidence of failure and had an extremely low mortality at six weeks. There was little evidence of benefit from lisinopril in these patients. For those who had some clinical evidence of failure overall mortality in the combined lisinopril treated and control patients was substantially higher. In those manifesting clinical failure the reduction in mortality was substantial. A similar pattern was recorded in those with and without overt failure before randomisation in ISIS-4.
It would be inappropriate to conclude that only patients with signs and symptoms of heart failure can benefit from ACE inhibitors. Indeed, among those without apparent clinical failure some 20-25% would be expected to have low ejection fractions and the potential for benefit. However, such benefit might not necessarily be expected to be apparent with short term treatment and follow up, as indicated by the observations in SAVE and the chronic left ventricular dysfunction studies (SOLVD treatment/prevention and V-HeFT II). The AIRE and SAVE findings indicate that clinicians using clinical acumen and other assessment of left ventricular dysfunction can identify those most likely to gain from treatment. Importantly, careful selection may protect some from harm.
Timing of treatment with ACE inhibition after myocardial infarction An important clinical issue is the timing of the start of treatment. After the findings of CONSENSUS II it is unlikely that much enthusiasm will be found for the use of an intravenous ACE inhibitor. Yet the confidence limits of this study cross those of both ISIS-4 and GISSI-3. Furthermore, as oral captopril is rapidly absorbed, the gain in onset of effect by intravenous compared with oral administration is only 45 minutes to one hour. Many patients in ISIS-4 received captopril within six hours of the onset of their chest pain against an average time of 15 hours for intravenous enalaprilat in CONSENSUS II. Although there may have been considerable overlap in timing of first achieving ACE inhibition, the intravenous and oral regimen in CONSENSUS II, given the different characteristics of long acting enalapril compared with short acting captopril, would almost certainly have produced longer lasting and more profound early ACE inhibition. In the AIRE study benefit was apparent whether patients were randomised before or after the fifth day, and patients in SAVE did not receive treatment until an average of 11 days after infarction. However, in the AIRE study even by the time of discharge from hospital more patients had died in the placebo group than in the ramipril group. In both these studies patients were clinically stable. Whereas early treatment seems desirable, delay in administration beyond the first day makes assessment of clinical stability and identification of patients most likely to benefit more certain and would seem prudent.
Can patients expect to gain above conventional treatment? The importance of early thrombolysis and aspirin treatment is beyond question, though even here some have much more to gain than others; a few will be harmed. Though the evidence for benefit from a blockers was all gained before the introduction of thrombolysis, it would be perverse to eschew their use. Intravenous a blockade has achieved little favour for use in the United Kingdom, yet the potential for lives saved per 1000 patients treated in the first ISIS trial was almost twice that seen with captopril in the most recent ISIS study. Recognition of the heterogeneity of the patients seems essential for sensible practice. At one end of the range 1 blockers seem obligatory, but when left ventricular function is obviously impaired their use may be inappropriate. For ACE inhibitors the converse situation obtains, with benefit beyond doubt for those with poor ventricular function after surviving the unstable first few hours after infarction. Between these extremes lie a broad group of patients who should benefit from both drugs, but probably to differing degrees. The illustrated in the prevention arm of the SOLVD study.6 Long term treatment with enalapril in "asymptomatic" patients with evidence of impaired left ventricular function did not significantly reduce mortality but decreased hospital admissions for heart failure. However, a caveat for any trial of this design is that it cannot distinguish true prevention from the effects of giving an active agent before the onset of symptoms, thereby merely treating in advance of actual need.
In the SAVE study showed without signs or symptoms of heart failure at randomisation who had impaired left ventricular function (indicated by a reduced radionuclide ejection fraction) benefited not only from longer survival but also from preservation of ventricular function as assessed by measurement of ejection fraction. Similarly, in the AIRE study patients with signs and symptoms of ventricular dysfunction, even if transient, lived longer and fewer exhibited deterioration of ventricular function assessed clinically. The observations of these two studies and the SOLVD prevention trial support a role for the ACE inhibitors in preventing deterioration of ventricular function. More difficult for the clinician is to decide the degree of left ventricular dysfunction which justifies treatment and how to assess that dysfunction reliably.
The potential for preventing reinfarction adds a further dimension. In the SAVE study patients receiving captopril had fewer myocardial infarctions as defined by the investigators than had those receiving placebo. The effect was less apparent for reinfarctions defined by the end points committee, and the effect disappeared if "silent reinfarctions" were included.23 The AIRE study was shorter, it had less than half the number of end point committee validated reinfarctions observed in the SAVE study, and only a marginal trend to fewer reinfarctions was seen in the group given ACE inhibitors. Furthermore, in the SAVE and AIRE studies patients who had a second infarction after the index infarction permitting entry into the trial had twice the mortality of patients without reinfarctions, but similar benefit from ACE inhibitors was seen in both groups in both studies. The preliminary findings of GISSI-3 and ISIS-4 with more than 2000 reinfarctions show no benefit from ACE inhibition, but the treatment was for a maximum of six weeks. Studies which prospectively address prevention of myocardial infarction in a wider group of patients to include those with apparently normal ventricular function are required to resolve this important issue.
Conclusion
A substantial proportion of patients after myocardial infarction can expect considerable benefit from treatment with ACE inhibitors.
Patients with the combination of clinical signs and symptoms of heart failure and low ejection fractions have most to gain and treatment should not be unnecessarily delayed.
Currently, prescriptions of diuretics for heart failure in the United Kingdom are estimated to be 10 times higher than those of ACE inhibitors. Doctors should ensure that the majority of these patients and those who are prescribed diuretics receive appropriate treatment with an ACE inhibitor, rather than be preoccupied with debating the marginal benefits.
